XURIDEN (uridine triacetate)
HEREDITARY OROTIC ACIDURIA TREATMENT AGENTS · HEREDITARY OROTIC ACIDURIA, TYPE I
BTG INTERNATION
Drug class
Hereditary Orotic Aciduria Treatment Agents
Hereditary orotic aciduria treatment agents are a specialized class of metabolic replacement therapies used to manage hereditary orotic aciduria, an extremely rare autosomal recessive inborn error of pyrimidine synthesis. Read more about Hereditary Orotic Aciduria Treatment Agents
1 drugs in this class 1 manufacturers
Drugs in Hereditary Orotic Aciduria Treatment Agents
Filter & compare in the drug finder →
Opens the drug finder with Hereditary Orotic Aciduria Treatment Agents preselected. Add indication or manufacturer filters there.
Hereditary orotic aciduria treatment agents are a specialized class of metabolic replacement therapies used to manage hereditary orotic aciduria, an extremely rare autosomal recessive inborn error of pyrimidine synthesis.
Primarily represented by the prodrug uridine triacetate, these agents function by providing exogenous uridine to bypass the enzymatic block caused by uridine 5'-monophosphate synthase deficiency.
Once converted to uridine and phosphorylated into uridine nucleotides, the therapy restores cellular RNA and DNA synthesis while exerting negative feedback on early pyrimidine biosynthesis to suppress excessive orotic acid production.
Consequently, this treatment prevents or reverses hallmark clinical manifestations, notably refractory megaloblastic anemia, urinary tract crystal obstruction, and developmental delays.
-
drugs.com
Hereditary orotic aciduria treatment agents are a specialized class of metabolic replacement therapies used to manage hereditary orotic aciduria, an extremely rare autosomal recessive inborn error of pyrimidine synthesis Primarily represented by the prodrug uridine triacetate, these agents function by providing exogenous uridine to bypass the enzymatic block caused by uridine 5′-monophosphate synthase deficiency
-
pharmaceutical-journal.com
Hereditary orotic aciduria treatment agents are a specialized class of metabolic replacement therapies used to manage hereditary orotic aciduria, an extremely rare autosomal recessive inborn error of pyrimidine synthesis Once converted to uridine and phosphorylated into uridine nucleotides, the therapy restores cellular RNA and DNA synthesis while exerting negative feedback on early pyrimidine biosynthesis to suppress excessive orotic acid production Consequently, this treatment prevents or reve...
-
fda.gov
Primarily represented by the prodrug uridine triacetate, these agents function by providing exogenous uridine to bypass the enzymatic block caused by uridine 5′-monophosphate synthase deficiency
-
fepblue.org
Primarily represented by the prodrug uridine triacetate, these agents function by providing exogenous uridine to bypass the enzymatic block caused by uridine 5′-monophosphate synthase deficiency Once converted to uridine and phosphorylated into uridine nucleotides, the therapy restores cellular RNA and DNA synthesis while exerting negative feedback on early pyrimidine biosynthesis to suppress excessive orotic acid production Consequently, this treatment prevents or reverses hallmark clinical man...
-
incitefulmed.com
Once converted to uridine and phosphorylated into uridine nucleotides, the therapy restores cellular RNA and DNA synthesis while exerting negative feedback on early pyrimidine biosynthesis to suppress excessive orotic acid production
-
pharmacytimes.com
Consequently, this treatment prevents or reverses hallmark clinical manifestations, notably refractory megaloblastic anemia, urinary tract crystal obstruction, and developmental delays
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.